The generic and biosimilar medicines industry globally, represented by the International Generic and Biosimilar medicines Association (IGBA), supplies the overwhelming majority of prescription medicines to patients worldwide, and strongly supports ongoing multilateral efforts to achieve a robust WHO Pandemic Agreement.

IGBA welcomes the opportunity to provide comments to the 30 October 2023 proposal for negotiating text of the WHO Pandemic Agreement. As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States in reaffirming the importance of multisectoral collaboration to safeguard human health and build stronger, more resilient health systems.

The International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Suzette Kox, the first IGBA Secretary General, has passed on the baton to Dr. Susana Almeida.